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Peripheral blood mononuclear cells from 22 pemphi-
gus patients with active disease and 30 normal subjects 
were evaluated for interleukin 2 (IL-2) production and 
IL-2 receptor expression following stimulation with 
phytohemagglutinin P (PHA-P). The IL-2 levels were 
lower in patients compared to corresponding controls 
and the production was delayed after PHA stimulation. 
This deficiency was most pronounced in severely af-
fected patients. IL-2 receptor appearance also was lower 
after PHA stimulation in a small number of patients 
tested. These results indicate that some cellular immune 
functions are altered in pemphigus. 
Pemphigus is an autoimmune, often fatal disease involving 
the skin and mucOUS membranes. There is in vivo deposition 
of IgG in the intercellular cement substance of the epidermis 
[1J. The serum contains an anti-intercellular cement substance 
(IeS) antibody of t he IgG class [2]. The titer of the antibody 
correlates with disease activity and severity [3]. When paSSively 
transferred into neonatal BALB/c mice, the antibody caused 
clinical and immunopathologic disease [4]. A decrease in the 
total number of T cells and a T -cell depletion in the paracortical 
areas of the lymph nodes have been observed in some pemphi-
gus foliaceus patients [5]. 
A study was undertaken to investigate the possible changes 
in the criticallymphokine, interleukin 2 (IL-2) and its receptor 
in pemphigus. IL-2 biosynthesis and IL-2 receptor expression 
were studied in patients with active pemphigus and correlated 
with disease activity, severity, and anti-IeS antibody titer. In 
further studies p roliferative response to phytohemagglutinin P 
(PHA-P) was measured in patients and compared to normals 
and the effects of purified IL-2 on the proliferative response 
was exp lored. 
MATERIALS AND METHODS 
Patients and Cont rols 
Twenty-two pemphigus vulgaris patients ranging in age from 18:-82 
(mean 58 ± 18) years, seen at the UCLA Medical Center were studied. 
Manuscript received October 20, 1983; accepted for publication April 
5, 1984. . 
Supported in part by NIH grants AI 20672, CA 09120, CA 12800, tn 
part by USPHS grant 5S07 RR 5354, and in part by a grant from the 
Concern Foundation of Los Angeles. 
Reprint requests to: A. R. Ahmed, M.D. , Division of Dermatology, 
52-121 CHS, UCLA Sc hool of Medicine, Los Angeles, California 90024. 
Abbreviations: 
BSA: bovine serum albumi n 
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PBMC: peripheral blood mononuclear cells 
PHA-P: phytohemagglutinin P 
TPA: l2-0-tetradecanoylphorbol -13-acetate 
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The patients had acute disease at t he time of the ini tia l study and were 
not on any system ic therapy. The diagnosis was made on t he basis of 
clinical features, routine histo logy, and immunofluorescent studies 
[6]. Patients were divided into categories of severity on the basis of 
clinical involvement and anti -ICS antibody titers. Patients with mild 
or 1 + disease had less than 30 lesions usually in one anatomic location 
and had anti -ICS antibody t iters of 0- 40. Patients with moderate or 
2+ disease had 40- 80 lesions in different anatomic areas and anti -ICS 
antibody titers of 80- 320. Patients with 3+ or severe disease had over 
80 lesions in ge neralized distribution and antibody titers of 640 or 
greater. Serum from each individual was assessed from anti- ICS anti -
body of the IgG isotype by t.he indirect immunofluorescence techn ique 
using monkey esophagus as the substrate 17J. Thirty normal individuals 
ranging in age from 20- 75 (mean 38 ± 14) years and 5 patients with 
other dermatologic diseases served as controls. The patient and control 
groups had similar sex distributions. 
Peripheral BLood Mononuclear CeLL~ 
Peripheral blood mononuclear cells (PBMC) were obtained from 
heparinized (20 units/ m!) blood by the Ficoll -Hypaque gradient method 
18] . Harvested cells were washed with RPMI 1640 (Irvine Scientific, 
Santa Ana, California) 3 times. Cells with greater than 95% viability 
were adjusted to I x lOo/ ml with RPMI 1640 contain ing penicillin (25 
units/ ml) , streptomycin (25 ng/ml) , glutamine (2 mM) (Irvine Scien-
tific), and 0.25% bovine serum albumin (BSA) (Sigma, St. Louis, 
Missouri). Wright's stain exami nation of t he suspensions demonstrated 
the cell population consisted of 10- 20% monocytes and 1- 10% poly-
morphonuclear leukocytes. 
In.terleukin-2 Production 
PBMC (1 x lOG) from patients or controls were cultured in 0.25% 
BSA with 10 Ilg phytohemagglutin in P (PHA-P) (Difco Laboratories 
Detroit, Michigan) for 24, 48, 72, 96, and 120 h. To determine th~ 
capacity of eac h specimen to produce IL-2, at various times the cells 
were removed by centrifugation and the supernatant.s were individually 
collected and tested on a mouse cytotox ic ce ll line (CTLL-2) for growth-
promoting activity [9]. 
Biologic Assay for /L-2 Activity 
Individual samples were tested for IL-2 activity by their abili ty to 
stimulate CTLL-2 to incorporate tritiated t hymidine [9]. The assess-
ment of the IL-2 activity in units/ml was based on linear in terpolation 
analys is of standard to normal and calculated according to the following 
formula 110] . 
IL-2 activity of sample (units/ ml) 
Reciprocal titer of test sample at 
30% of max imal cpm of standard 
Reciprocal t iter at 30% of maximal 
cpm of standard 
where 100 is the number of units/ml for standard. 
Respons iveness to PHA -P 
The response of PBMC to PHA-P was studied. PBMC (2 x 10' ) 
from patients or controls were cultured for 72 h in a Cook microtiter 
plate (Microbiological Associates, Los Angeles, California) with 10 Ilg 
PHA-P / ml and 10% fetal calf serum (FCS) (Irvine Scientific) as 
described earlier r ll] . 
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Praliferative Effect af I L-2 
The enha ncing effect of IL-2 on PBMC response to PHA-P was 
dete rmined. In pre limin a ry experiments IL-2 ra nging from 1- 30 units 
per I x lO" ce lls in cultures was added. The cultures conta ined 2 X 10" 
cell s. IL-2 was added J 0 min to 1 h a fter PHA stimulation. IL-2 was 
prepared a nd purified as previously described [1 2]. 
Enumeration of /L-2 Receptor-Bearing Cells 
Qua ntificat ion of lL-2 receptor-bearing ce lls was pe rfo rmed on fresh 
or cultured mononuclear ce lls. Tac a nt igen expressed on surface of 
lymphocytes was determined using a flow cytometer (Spectrum III , 
Ortho Diagnost ics System, Westwood, Massachusetts ). The PBMC 
ce lls, fresh a nd cultured , were incubated for 45 min with murine 
monoclona l ant i-Tac antibody {provided by Dr. Waldma n, N IH , Be-
t hesda, Maryland, washed , incubated for an additional 45 min with 
fluorescein -conjugated rabb it antimouse 19 a n tisera {Becton-Dickin -
son, Mountain View, California), and enumerated by t he automated 
flow cytomete r. Murine IgG 2n myeloma protein (RPC-5, Bionetics, Inc, 
Bethesda, Ma ryland) was used as control t o determine nonspecific 
binding. 
tatisties 
Two group comparisons were done using t he t-test and the Wilcoxon 
rank sum test. A significan t resul t was reported if it was significant on 
both tests. As t he comparisons were done at 5 prespecilied time points , 
t he p value was adjusted for mul t iple compa risons using Bonferroni's 
method [13]. 
RESULTS 
IL-2 leve ls were determined at 24, 48, 72, 96, and 120 h in 
each patient and cont rol following mitogenic (PHA) stimula-
tion (Fig 1). At 24 and 48 h, the level of IL-2 production was 
significantly lower in patients when compared to controls (p < 
0.0.5). In t he control group, IL-2 production rapidly increased 
and atta ined max imum levels after 48-72 h and declined after 
96- 120 h. In the pemphigus patients, IL-2 production was 
generally delayed and its level did not increase as rapidly as in 
the control group . 
Patients with mild or moderate disease produced decreased 
leve ls of IL-2 at 24 and 48 h when compared to controls (Fig 
2). The differe nces were not, however, statist ically sign ificant. 
IL-2 levels gradually increased in most patients with mild or 
moderate disease after 24 h. Those with severe disease showed 
the lowest IL-2 levels at 24, 48, and 72 h. When compared to 
contro ls, t his group showed significantly reduced IL-2 produc-
tion at 24 and 48 h (p < 0.05). At 96 and 120 h readin gs were 
available for less than one-half and one-third, respectively, of 
patients and controls. T hus results obtained at these times 
should be cautiously interpreted due to the small number of 
patients studied at these time intervals. 
Repeat tests were performed on 4 patients with severe disease 
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FIG 2. Compa rison of IL-2 biosynthes is in pemphigus pa tients {11 
severe, 6 modera te, and 5 mildly affected}. T hirty norma l individua ls 
were tested s imulta neous ly. 
and 4 controls to dete rmine reproducibility . Data shown in 
Table I confirm that IL-2 product ion in these 4 patients with 
seve re disease was similarly depressed on repeat observations . 
IL-2 is known to playa major role in proliferative response 
to mitogens, such as PHA. The PBMC from the ] 0 patients 
and the 10 controls demonstrated a wide range of proli ferative 
responsiveness with mean ["HJthymidine uptake of 120 ± 60 x 
10" cpm for normals and 60 ± 36 x 10" for patients (Fig 3) . 
However, if patients with severe disease are segregated t here is 
a marked reduction in the PHA response. These patients 
showed ["HJthymidine incorporation of only 27 ± 5 X 10:\ cpm 
compared to 120 ± 60 x 10:1 cpm for controls. The difference 
between these values is not statistically sign ificant. However 
it is possible that this is a real difference but that the small 
sample size does not allow this to be demonstrated statistically. 
IL-2 receptor expression after PHA stimulation was evalu-
ated in several experiments. Tac antige n (lL-2 receptor) expres-
sion was gradually increased on cul tured PBMC from 0 to 72 
h in both 7 normals and 7 patients (Fig 3). The frequency of 
expression of the IL-2 receptor was generally less in patients 
compared to t he cont rols at each t ime interval. This difference 
was more pronounced in patients with severe disease compared 
to those with mild or moderate activity (data not shown) . 
Preliminary studies indicated t hat t hose with high response 
to PHA often had litt le response to added IL-2. Therefore 
PBMC from 5 normals and 5 patien ts with low PHA response 
(below 50 x 10" cpm) were exposed to PHA and purified IL-2 
(10 uni ts/IOn cells) and t hen the proliferative response was 
assessed after 72 h of culture. The cultures conta ining IL-2 in 
addition to PHA showed a greater magnitude of [:lHJthymidine 
incorporation in patients and cont rols than cu ltures conta ining 
P HA or IL-2 alone (Fig 4). Although the statistical significance 
of this result is not determined due to t he small sample size, 
the increment in the proliferative response was greater than 
t he sum of the responses to PHA and IL-2 sepa rate ly, indicating 
that IL- 2 had some enhancing effect on proliferation in these 
cul tures. 
DISCUSSION 
IL-2 is a soluble factor produced by stimulated T cells [14J. 
Both helper/ inducer and suppressor/cytotox ic T ce lls interact 
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TABLE I. Kinetics of 1 L-2 production observed ill repeat testing 
Donor Age/Sex Severi ty of Antibody IL-2 activity (units/ml) from PBMC at; disease tit.er no. 24 h 48 h 72 h 96 h 120 h 
Pemphigus 
12A" 53 F 3+ 640 0 17 15 12 13 12B 53 F 3+ 640 0 0 0 0 0 JOA 70 M 3+ 320 24 N.Db N.D. N.D. N.D . 
lOB 71 M 3+ 320 13 27 11 N.D. N.D. llA 39 F 2+ 160 0 0 0 0 0 llB 39 F 3+ 320 0 0 0 15 4 8A 70 F 3+ 320 2 4 3 3 3 8B 70 F 3+ 320 0 0 0 0 
NormaL 0 
24A 43 M 270 350 250 20 20 
24B 43 M N.D. 182 62 N .D. N.D. 
22A 75 M 32 138 N.D. N.D. N.D. 
22B 75 M 33 227 750 750 N .D. 
23A 22 M 234 170 N.D. N.D . N .D. 
23B 22 M N.D. 138 N.D. N.D. N.D. 
20A 70 F J09 22 1 97 32 12 
20B 70 F 68 98 9 N.D. N.D. 
a A and B represent repeat of samples from same individual at two different intervals. 
b N.D. == not done. 
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FIG 3. Kinetics of Tac OL-2 receptor) express ion in 10 pemphigus 
patients (mildly to severely affected) a nd 10 normal individuals. PHA 
p ro liferative response of these patIents and normals at 72 h. Cultures 
a re included. 
with IL-2 molecules via specific receptors [15,16) . Such recep-
tors are detected by the anti-Tac monoclonal antibody (15). 
Both IL-2 production and IL-2 receptor expression are key 
events in t he cascade of ce llular even ts leading to proliferation 
of increased T cells and preparation for immune function 
[10,17,18). In several strains of mice that develop autoimmune 
disease, defi ciencies of IL-2 production have been reported 
[19,20) that co rrelate with di sease manifestations and severity. 
Recent observations indicate that such phenomena also may 
be present in human patients with systemic lupus erythema-
tosus [21,22J. 
In t his study PBMe of patients with pemphigus responded 
to P HA with lower levels of IL-2 activity in culture superna-
tants compared to normals. This decreased activity is more 
pronounced in patients with severe disease and higher anti-IeS 
antibody t iters. Decreased IL-2 receptor expression also paral-
leled the disease extent and anti- IeS ant ibody t iters. 
Several studies have focused on the ant ibody aspects and the 
autoimmune nature of pemphigus. This study emphasizes t he 
coexistence of di so rders of cellular immune regu latio n in pem -
phigus. While it is not clear whether these cellular immmune 
changes are primary or secondary to the disease, it is possible 
t hat they contribu te to some of the manifestations. Indeed, 
disorders of immune regulation a re postulated to be t he basis 
for expression of autoantibodies [23 J. 
T he T -cell changes in pemphigus described here are t he slow 
generation of IL-2 and reduced expression of IL-2 receptor. 
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These could result from excessive suppressor activity, either of 
monocytes or of T cells. Preliminary efforts, however, to dem -
onstrate excessive suppressor activity did not support t his 
possibility. In 4 experiments, PBMe from pemphigus patients 
were irradiated with 1000 rad or passed through nylon wool 
columns to reduce suppressor cell activity (24J or were treated 
with indomethacin, a known inhibitor of prostaglandin E- there 
was no change in IL-2 production. No evidence of suppr~ssion 
of IgG secretion was observed in one study [25). In another 
study no loss of suppressor T-cell function was observed in 
mononuclear cells from pemphigus patients using concanavalin 
A induction techniques [26]. 
Deficiency of IL-l production or response to IL-l can resul t 
in the decreased production of IL-2. In additional studies when 
12-0-tetradecanoylphorbol -13-acetate (TPA), an agent that at 
least in some systems mimics the activity of IL-1 [16,27], was 
added to cells from 4 patients' cells that had negligible IL-2 
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production, and no significant alteration of IL-2 production 
was observed. However, t he role of exogenous IL-l instead of 
TP A was not tested . 
In additiona l preliminary studies, it was observed that exog-
enous IL-2 can exert an enhancing influence on cellular re-
sponse to PHA. This effect was pronounced in individuals with 
a decreased pro liferative response. However, the patien ts with 
low PHA response were compared to normals with low P HA 
response also. This was done to eliminate the variable of 
baseline response and, hence, it appears that the enhanced 
effect of exoge nous IL-2 is a demonstration of the effec t of IL-
2 on patient PBMC. The significance of this result remains to 
be elucidated. 
Furt her studies are needed to enhance the understanding of 
the cellular and molecular mechanisms of autoantibody for-
mation and the role of cells of the immune system in t he 
pathogenesis of pemphigus. 
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